Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
6.39
+0.12 (1.91%)
Jan 22, 2026, 8:48 AM EST - Market open
Bolt Biotherapeutics Revenue
Bolt Biotherapeutics had revenue of $2.17M in the quarter ending September 30, 2025, with 90.10% growth. This brings the company's revenue in the last twelve months to $5.20M, down -46.88% year-over-year. In the year 2024, Bolt Biotherapeutics had annual revenue of $7.69M, down -2.36%.
Revenue (ttm)
$5.20M
Revenue Growth
-46.88%
P/S Ratio
2.31
Revenue / Employee
$99,904
Employees
52
Market Cap
12.27M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.69M | -186.00K | -2.36% |
| Dec 31, 2023 | 7.88M | 2.15M | 37.48% |
| Dec 31, 2022 | 5.73M | 4.47M | 354.68% |
| Dec 31, 2021 | 1.26M | 1.03M | 445.45% |
| Dec 31, 2020 | 231.00K | 16.00K | 7.44% |
| Dec 31, 2019 | 215.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBOLT News
- 2 months ago - Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 - GlobeNewsWire
- 5 months ago - Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 9 months ago - Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 9 months ago - Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - GlobeNewsWire
- 9 months ago - Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - GlobeNewsWire
- 9 months ago - Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire
- 10 months ago - Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire